Sleep quality
Conditions
Interventions
Observation group (Intravenous esketamine):None
Sponsors
The Third Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients scheduled for elective, first-time, unilateral total knee replacement surgery; 2. Patients aged 18 to 75 years; 3. American Society of Anesthesiologists (ASA) classification levels I-III: (ASA Level I: Patients without systemic diseases except localized lesions; 1.ASA Level II: Patients with mild, well-controlled systemic diseases without significant functional limitations; 2.ASA Level III: Patients with at least one poorly controlled or end-organ-damaging systemic disease causing substantial functional limitations); 4. Patients with clear consciousness, adequate cognitive and communication abilities to understand study content and cooperate with relevant scale assessments (e.g., VAS, PSQI, HADS) and information collection; 5. Patients have provided full informed consent and voluntarily signed a written informed consent form.
Exclusion criteria
Exclusion criteria: 1. The patient or their legal representative refuses to participate in this study; 2. History of severe neurological disorders (e.g., dementia, Parkinson's disease, epilepsy, severe post-stroke functional impairment), psychiatric disorders (e.g., schizophrenia, bipolar disorder), or confirmed substance/alcohol abuse; 3. Known hypersensitivity to esketamine or any of its excipient components, or contraindications (e.g., uncontrolled hypertension, severe heart failure, increased intracranial pressure, glaucoma, acute schizophrenia); 4. Long-term preoperative use (over 4 weeks) of medications affecting central nervous system, sleep, anxiety, or depression (e.g., benzodiazepines, antidepressants, antipsychotics) that cannot be discontinued during the study; 5. Patients scheduled for surgery after 3:00 PM to avoid significant circadian rhythm disruption from late surgical completion; 6. Refusal to use postoperative analgesia pump; 7. Concurrent severe systemic diseases (e.g., severe hepatic/renal insufficiency, uncontrolled coagulation disorders, immune system diseases) deemed unsuitable by investigators for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sleep quality; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative emotional indicators;Postoperative pain index; | — |
Countries
China
Contacts
Public ContactZhang Xiaoyu
The Third Affiliated Hospital of Guangzhou University of Chinese Medicine
Outcome results
None listed